Analystreport

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is now covered by analysts at TD Cowen. They set a "buy" rating and a $65.00 price target on the stock.

Protagonist Therapeutics, Inc.  (PTGX) 
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.protagonist-inc.com